Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Conditions: Pancreatic Cancer
Interventions: Drug: Talimogene laherparepvec
Sponsors: Karie D. Runcie, MD; Amgen
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 10, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments